The production of biopharmaceuticals in Brazil: current issues by Pimenta, Marcela Valente & Monteiro, Gisele
Braz. J. Pharm. Sci. 2019;55:e17823 Page 1 / 8







*Correspondence: G. Monteiro. Departamento de Tecnologia Bioquímico-
Farmacêutica, Faculdade de Ciências Farmacêuticas, Universidade de São 
Paulo, São Paulo, Brazil. Tel.: +55 11 3091-3734. E-mail: smgisele@usp.br
The production of biopharmaceuticals in Brazil: current issues
Marcela Valente Pimenta1, Gisele Monteiro 1*
1Department of Biochemical-Pharmaceutical Technology, Faculty of Pharmaceutical Science,  
University of Sao Paulo, SP, Brazil
Biopharmaceuticals are gaining a growing share of the pharmaceuticals market. In recent years, the 
Brazilian Health Surveillance Agency (ANVISA) has approved the registration of biological drugs with 
domestic production. Although Brazil is in the early stages of biopharmaceutical production, governmental 
incentives and the investment in private companies in the technological domain in this country have 
created expectations of an increase in the capacity of biopharmaceutical production. Private initiatives, 
once rare, have now started to blossom in this field, such as collagenase from Cristalia and filgrastim 
from Eurofarm. The expiry of the patents for certain biopharmaceuticals (e.g. infliximab, filgrastim and 
rituximab) has generated the possibility of savings to the Brazilian National Health System (SUS) in terms 
of biosimilars and incentives for national production. National production could also avoid dependence 
on external imports and a lack of essential supplies. In the next few years, Brazil is expected to bring 
nationally produced biopharmaceuticals to the market. Although there is some way to go before Brazil 
will be able to sustain the national demand for biopharmaceuticals and supply international markets with 
new products, the country is starting to take its first steps towards these objectives. 
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INTRODUCTION
According to the Food and Drug Administration 
Agency (FDA), biopharmaceuticals are complex 
molecules produced by an organism or a cell, and are 
used in medicine for healing, remedial, corrective or 
restorative replacements or treatments (FDA, 2017). 
Biopharmaceuticals can be broadly divided into three 
main classes: therapeutic proteins (e.g. asparaginase, 
insulin and imiglucerase), monoclonal antibodies (mAb, 
e.g. infliximab and adalimumab) and vaccines. In 1978, 
scientists from Genentech created the recombinant 
hormone insulin, produced by Escherichia coli. This 
was the first biopharmaceutical using recombinant DNA 
technology. Before this, insulin had been obtained from 
porcine and bovine pancreas, and faced obstacles to 
large-scale production, and adventitious and dangerous 
contaminants such as viruses (Tibaldi, 2012). 
Nowadays, the pharmaceutical market offers several 
types of insulin, including short-, intermediate- and long-
acting forms and biphasic insulins that can reduce the 
number of injections required. The natural biosynthesis 
of insulin starts with a peptide in which the amino-
terminal portion contains a signal-sequence, followed 
by a segment called the B chain, an intermediated linker 
called the C chain, and an A chain in the carboxy-terminal 
portion. During processing, the signal-sequence and the 
C chain are cleaved, and two disulphide bonds contain 
chains A and B. In human recombinant insulin, only the 
A and B chains are synthesised by E. coli. Both peptides 
are linked by disulphide bounds through a redox process 
(Tibaldi, 2012; Goeddel et al., 1979). DNA recombinant 
technology offers the possibility of treating diseases 
caused by a lack of peptide hormones or even enzyme 
deficiency. 
In the 1970s, the native E. coli enzyme asparaginase 
began to be used as a biopharmaceutical in leukaemia 
treatment. Asparaginase catalyses asparagine (Asn) 
hydrolysis in glutamine (Gln) and ammonium. Leukemic 
cells are dependent on an external source of Asn, which is 
depleted in the serum by the use of asparaginase, causing 
proper protein synthesis to fail and apoptosis to be initiated 
(Avramis, 2012). Asparaginase and insulin are peptides 
with no requirement for sophisticated post-translational 
modification (PTM), such as in glycosylation.
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With an increase in PTM complexity, the organism for 
heterologous expression needs to be more evolved. Yeasts 
such as Saccharomyces cerevisiae and Pichia pastoris can 
be used to produce glycoproteins, instead of bacteria such 
as E. coli. However, the glycosylation pattern is different 
to that found in humans, causing an unwanted immune 
response in the patient (Josala et al., 2016; Scott, Allison, 
Wolchok, 2012).
The expression platform most often used to produce 
recombinant glycoproteins is Chinese hamster ovary cells 
(CHO), since these have a glycosylation pattern close to 
that in humans, grow in suspension, have a lower chance 
of contamination with human viruses and have been very 
well accepted by regulatory agencies for the approval of 
drugs (Durocher, Butler, 2009).
Glycosylation requirements affect the production 
of one of the most important class of biopharmaceuticals, 
the mAb. The possibility of using mAb to target cell 
receptors vastly increased the number of available 
therapies. Infliximab and adalimumab are examples of 
mAbs targeting the tumour necrosis factor alpha (TNF-α) 
pathway, and are used in many conditions to control 
inflammation, such as in rheumatoid arthritis, Crohn’s 
disease and psoriasis (Kalden, Schulze-Koops, 2017). 
In terms of cancer therapy, mAbs are used for several 
aims, such as cell growth factors (e.g. trastuzumab - Her2, 
bevacizumab - VEGF, cetuximab and panitumab - EGFR), 
tumour antigens (e.g. rituximab, ofatumumab, alentuzumab 
and ofatumumab), immune checkpoints, restoring the 
ability of T cells to fight cancer (e.g. ipilimumab), or even 
for the delivery of toxic payloads or radioisotopes (e.g. 
gemtuzumab, brentuximab vedotin, 90Y-ibritumomab and 
131I-tositumomab) (Kesik‐Brodacka, 2018; Scott, Allison, 
Wolchok, 2012; Tsai, Hsu 2017).
The market share of biological drugs is increasing 
each year. Projections indicate a value of USS 287 bn 
by 2020, led mainly by mAb and insulins (Walsh, 2014; 
Transparency Market Research, 2018).
Due to the high cost of this class of medicine and 
the new technologies used in the fabrication process, 
Brazil is in the early stages of domestic production of 
biopharmaceuticals. The aim of this review is to position 
Brazil in the context of biopharmaceutical production.
Biopharmaceutical production – overview of the 
problem
A biological drug is significantly more complex 
than a synthetic drug. For example, the synthetic drug 
paracetamol has a molecular weight of 151.15 g/mol, 
and the chemical formula C8H9NO2, while infliximab, 
an mAb, has a molecular weight of 144,190.3 g/mol and 
the chemical formula C6426H9912N1694O1987S46, i.e. three 
orders of magnitude greater (Figure 1). It is economically 
infeasible to synthesise a complex structure such as a 
biological drug by chemical means.
The expiry of the first biopharmaceutical patents 
opened the way for the pharmaceutical industry to 
produce and commercialise the same biological drugs 
under different trademarks (Tsuruta, Santos, Moro, 2015). 
However, in the specific case of biopharmaceuticals, the 
process of ensuring regulatory equivalence for a new 
trademark is much more complicated than that necessary 
for synthetic drugs, due to the greater possibility of 
differences in the processing of biological molecules 
having a direct impact on their quality and therapeutic 
effects. 
Biosimilars have the same relat ionship to 
biopharmaceuticals as that of generic drugs to synthetic 
ones. Infliximab was the first biosimilar mAb approved 
by the European Medicines Agency (EMA). Remsima®, 
produced by Celltrion Healthcare©, was recently approved 
FIGURE 1 - Comparison of a synthetic drug with a biological drug. A: the structure of Paracetamol, a small molecule usually used 
as an analgesic and antipyretic. B: The structure of Infliximab, a monoclonal antibody (mAb) used in rheumatoid arthritis treatment 
among other diseases. Adapted from: https://www.drugbank.ca.
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in 2013; the reference drug for this was Remicade®, 
produced by Janssen Global Services© which had been 
authorised by EMA since 1999. In process of regulation 
of Remsima®, different methodologies were utilised to 
access the molecule feature and ensure similar efficacy 
for the drug. Its protein structure, purity and glycosylation 
were studied using sophisticated techniques such as 
circular dichroism spectroscopy, differential scanning 
calorimetry, enzyme-linked immunosorbent assay 
(ELISA), electrospray ionisation mass spectrometry 
(LC-ESI-MS), size-exclusion chromatography and cell-
based assays, among others (Tsuruta, Santos, Moro, 
2015). These aspects mean that the regulatory process 
for biosimilars is more complex than for generic drugs 
(Kesik‐Brodacka, 2018).
In addition to the factors described above, the cost 
of treatment with biological drugs is usually higher than 
for synthetic drugs. For example, annual treatment of 
rheumatoid arthritis in the United States with conventional 
drugs costs US$755, compared to US$15,933 with 
biological drugs (Transparency Market Research, 2018). 
The Brazilian Context
According to a UNESCO Science Report (UNESCO, 
2015), Brazil is the only Latin American country with 
levels of investment in research and development 
(R&D) and scientific production equivalent to that 
of emerging economies. With a 2.9% share of global 
publications, Brazil is a major player in the fields of 
science, technology and innovation in Latin America. 
However, the country’s pharmaceutical companies have 
low levels of R&D investment, and encounter difficulties 
in bringing innovations onto the market (UNESCO, 2015). 
The Brazilian National Health System (SUS, Sistema 
Único de Saúde) divides the acquisition of medicines 
into three groups; basic, strategic and specialised. For 
specialised medicines (Groups 1A and 1B), the financing 
is exclusive to the Brazilian Government, and SUS 
expenditure was R$7.1 billion in 2016. Alongside many 
synthetic drugs, this subdivision contains most of the 
biopharmaceuticals; the exception is vaccines, which 
fall into the strategic group. More than 50% of the above 
SUS expenditure was on biopharmaceuticals, despite 
the fact that they represent only 4% of the total quantity 
of medicines acquired (Portal da Saúde, 2018). This 
discrepancy highlights the need for national production 
of biological drugs. Moreover, national production 
would diminish the dependency on the external market. 
There is frequently a lack of national supply of medicines 
due to commercial issues. In August 2012, the Oso 
Biopharmaceutical company informed several countries 
of their suspension of L-asparaginase production, leading 
to a lack of this essential drug for leukaemia treatment in 
Brazil (Brasil, 2017a).
In 2015, ANVISA approved the first biosimilar 
for national commercialisation, Remsima® (infliximab). 
This had first been approved by EMA in 2013 (Tsuruta, 
Santos, Moro, 2015), and the reference drug for this was 
Remicade® (© Janssen-Cilag). This approval created the 
possibility of a reduction in the cost of the medicine, since 
biosimilars have a lower price than the reference product. 
Remicade® is made in Switzerland, Ireland, Belgium and 
United States of America (USA), whereas the biosimilar 
Remsima® is produced in South Korea by Celltrion Inc. 
Biopharmaceutical production in Brazil
Biobrás, a pioneer company in the development 
of biopharmaceuticals in Brazil, started the insulin 
purification of bovine and porcine pancreas origin and 
delivered the feedstock to Eli Lilly, which purified and 
formulated the insulin in the final product. In 1983, 
Briobrás became a pharmaceutical company, and no longer 
supplied raw material to Eli Lilly. Despite having achieved 
large-scale production of recombinant human insulin in 
1999, Biobrás did not continue in business due to the 
low prices offered by the international market. In 2001, 
Biobrás was acquired for US$31 million by Novo Nordisk 
(Ferreira, 2008). In October 2017, Biomm (a successor 
of Biobrás) announced a partnership with MannKind 
Corporation (California, USA) to register with ANVISA 
and commercialise Afrezza®, an inhaled form of insulin 
(taken from Biomm website, Table II).
Brazil is self-sufficient in the production of several 
types of vaccines; for example, vaccines against hepatitis 
B, diphtheria, tetanus, and pertussis are produced by 
the Butantan Institute, an intradermal BCG vaccine by 
Fundação Ataulpho Paiva, and yellow fever vaccine 
by Bio-manguinhos/Fiocruz. These institutions have 
also formed partnerships with for-profit producers 
such as GSK (technology transfer agreements with 
Bio-manguinhos/Fiocruz to produce vaccines for Hib 
(Haemophilus influenzae b), OPV (oral polio vaccine), 
Rotavirus (monovalent oral human rotavirus vaccine), 
Pneumococcal 10-valent conjugate vaccine and MMR 
(measles, mumps, and rubella)); Novartis (technology 
transfer agreement with Fundação Ezequiel Dias, MG, 
to produce meningitis C conjugate vaccine) and Sanofi 
Pasteur (technology transfer agreements with Instituto 
Butantan to produce seasonal influenza and H1N1 
influenza vaccines). All of these biopharmaceuticals are 
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produced for a free vaccination program undertaken by 
the Health Ministry to immunise Brazilian citizens (for 
a complete review of Brazilian vaccines, see Ho et al., 
2011).
Partnerships for productive development
The Brazilian pharmaceutical industry benefits from 
government incentives to improve the national production 
of medicines with high cost. Partnerships for productive 
development (PDP, Parcerias para o Desenvolvimento 
Produtivo) between public and private institutions have 
been formed for the production of strategic medicines 
for the Unic Brazilian health system. In March 2017, the 
Health Ministry (MS, Ministério da Saúde) published 
a list of strategic interest products, which contained 56 
pharmaceutical components for Brazilian development, 
of which 23 were biopharmaceuticals (Table I). The 
Health Ministry planned to provide facilities for the 
national manufacturing of these components. It received 
83 proposals for production, 15 of which involved 11 
biopharmaceuticals (Brasil, 2017b; Brasil, 2017c). The 
MS approved eight proposals for biopharmaceuticals, 
to produce adalimumab, agalsidase beta, certolizumab, 
golimumab, imiglucerase, insulin glargine, palivizumab 
and tocilizumab (DOU, 2018; Table I). Future PDP 




In  order  to  reach a  level  of  in ternat ional 
competitiveness, some Brazilian pharmaceutical 
industries formed joint ventures. Bionovis is a joint 
venture involving Aché, EMS, Hypermarcas and União 
Quimica; these companies have formed a partnership with 
Janssen and Merck, who have agreed to supply them with 
production technology including a master cell bank for 
eight biopharmaceuticals. In addition, other products have 
been developed internally. In the pipeline for production 
by Bionovis are trastuzumab, bevacizumab, etanercept, 
rituximab, adalimumab, and two other drugs that have 
been developed (Bionovis website, Table II). 
Orygen Biotecnologia is a joint venture formed 
by Biolab,  Cristál ia and Eurofarma in order to 
research, develop, produce, commercialise and import 
biopharmaceuticals. However, no product has yet been 
registered with ANVISA, and no publications about which 
drugs are being developed have been produced (CADE, 
2013).
The pharmaceutical company Libbs has built its own 
plant, called Biotec, to produce mAb biopharmaceuticals, 
and the production of rituximab, etanercept, bevacizumab 
and adalimumab is currently planned. Although production 
has already started in Brazil, these products have not yet 
been launched on the market. Libbs has also registered 
trastuzumab, which will be produced by PDP (Libbs 
website, Table II). 
A public company called TECPAR, (TECPAR 
website, Table II) has established the production of 
immunobiologicals mainly for veterinary use, for 
example the rabies vaccine. It has set up projects 
to produce trastuzumab, infliximab, rituximab, 
adalimumab, bevacizumab and etanercept for SUS, and 
also intends to produce agalsidase beta, imiglucerase and 
haemoderivatives.
EuroFarma produces the first biosimilar to be entirely 
manufactured in Brazil, called Fiprima® (filgrastim), 
and began the commercialisation of this in 2016. The 
reference product is Granilokine® Roche. Filgrastim is a 
human granulocyte colony stimulating factor (G-CSF), a 
non-glycosylated protein from a prokaryotic source used 
to treat neutropaenia, mostly in an oncological context 
(DOU, 2015). 
Commercial permission for drugs in Brazil is 
granted by ANVISA, through a drug registration process. 
These registers are public and can be accessed through 
the website http://portal.anvisa.gov.br/consulta-produtos-
registrados, which contains fields allowing the registration 
of national and international manufacturers. Registration 
of the manufacturer only constitutes authorisation for 
manufacture, and does not necessarily mean that drugs 
are produced in this particular locality. From the records 
of filgastrin found to date (7th December 2017), Aché 
and Blau have also registered filgrastin with a national 
manufacturer; however, in ANVISA, this registration 
appears for another international manufacturer. From 
publicly available knowledge, it is therefore impossible to 
say whether this drug is produced in Brazil, abroad or both.
The same situation holds for the interferon Alfa-
2b recombinant used in the treatment of leukaemia and 
melanoma, among other diseases. It is commercialised 
by Biosintética and Fundação Oswaldo Cruz, and both 
ANVISA registrations contain an international and a 
national manufacturer. Erythropoietin has six Anvisa 
registrations, which four have domestic and international 
manufacturers: Biosintétic (from the Aché group), Blau 
(with two registers; Alfaepoetina® and Eritromax®), and 
Fundação Oswaldo Cruz. 
Cristália owns plants that produce biopharmaceuticals 
from prokaryote or eukaryote expression platforms. 
Trastuzumab, etanercept and somatotropin are undergoing 
the clinical trials required for the registration of biological 
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TABLE I - Biopharmaceutical in the List of Strategic Interest Products and Proposals received
Biopharmaceutical Class Function
PDP Proposals 
public institutions + private 
institutions
Abatacept mAb anti-inflammatory -
Alpha-galactosidase enzyme Fabry’s disease treatment -











Galsufase enzyme Mucopolysaccharidosis VI treatment -
Ipilimumab mAb cancer treatment -
Asparaginase enzyme acute lymphoblastic leucemia treatment -
Peg-asparaginase enzyme acute lymphoblastic leucemia treatment -
Natalizumab mAb multiple sclerosis treatment -
Botulinum Toxin acetylcholine blocker Dystonia treatment -
Adalimumab1 mAb anti-inflammatory Butantan institute + Libbs TECPAR Approved
Adalimumab2 mAb anti-inflammatory Biomanguinhos + Bionovis Disapproved
Adalimumab3 mAb anti-inflammatory +Orygen Biotecnologia Disapproved
Agalsidase beta enzyme Fabry’s disease TECPAR+Genzyme Approved
Certolizumab pegol mAb anti-inflammatory Biomanguinhos + Bionovis Approved
Golimumab mAb anti-inflammatory Biomanguinhos+Bionovis Approved
Imiglucerase enzyme Gaucher’s disease TECPAR+Genzyme Approved
Insulin Aspart insulin analogue Type 1 or 2 diabetes mellitus Bahia Farma+Indar Disapproved
Insulin Glargine1 insulin analogue Type 1 or 2 diabetes mellitus
FUNED+Biomm 
Butantan + Gan & Lee 
Pharmaceuticals
Approved
Insulin Glargine2 insulin analogue Type 1 or 2 diabetes mellitus Bahiafarma+INDAR Disapproved
Insulin Glargine3 insulin analogue Type 1 or 2 diabetes mellitus Butantan+Sanofi Aventis Disapproved
Nivolumab mAb cancer treatment Biomanguinhos + Bionovis Disapproved
Palivizumab mAb respiratory syncytial virus. Butantan + Libbs Approved
Pembrolizumab mAb cancer treatment Biomanguinhos + Bionovis Disapproved
Tocilizumab mAb anti-inflammatory Biomanguinhos + Bionovis Approved
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drugs with ANVISA (https://www.cristalia.com.br/
biotecnologia). A phase III clinical trial of Somatotropin 
is registered at http://ensaiosclinicos.gov.br/rg/RBR-
85bbp4/, and the equivalent for trastuzumab is registered 
at http://clinicaltrials.gov/ct2/show/NCT03242239?ter
m=trastuzumab+crist%C3%A1lia&rank=1. Currently, 
collagenase is the only biopharmaceutical produced by 
Cristália’s biotechnology division, and has been registered 
with ANVISA and commercialised since 2016. This is the 
first biopharmaceutical derived from the Brazilian biome. 
A native strain of Clostridium histolyticum produces the 
enzyme collagenase by means of anaerobic fermentation, 
which is marketed as an ointment for the treatment of 
burns and other skin lesions (Pacheco, 2017). Further 
efforts are ongoing to develop collagenase for tissue 
dissociation (e.g. stem cells, isolation of pancreatic islets) 
as a high-grade ingredient.
Cristália’s collagenase is the first biopharmaceutical 
in the world that not does use animal derivatives for the 
C. histolyticum culture. This animal-free formulation 
of collagenase follows the guidelines of the main 
international regulatory health agencies, avoiding possible 
contamination with viruses or prion diseases. This aspect 
allowed Cristália’s collagenase to be granted a US patent 
in 2017, the first time in the history of Brazil that it has 
been possible to export the technology used to produce a 
biopharmaceutical (Alegria et al., 2017; Pacheco, 2017). 
After extensive searching of the database of 
medicines registered with ANVISA (ANVISA, 2017) 
and of the websites of major pharmaceutical and public 
companies (Table II), the authors of this article could 
find only two entirely Brazilian biopharmaceuticals 
that were registered with ANVISA and in commercial 
production; these were Fiprima®, a biosimilar produced 
by Eurofarma, and Kollagenase®, produced by Cristália. 
Other biopharmaceuticals are undergoing the production 
phase and clinical trials, although due to the confidential 
nature of the pharmaceutical industry, it is not possible to 
access these data. For safety reasons, ANVISA requires 
that all registered biosimilars undergo clinical trials, which 
is very expensive and time-consuming. There are two 
ways to register a biosimilar in ANVISA: the first uses a 
comparison method, and the second involves individual 
development. The procedures for these are described in 
RDC nº55/2010. 
In  contras t  to  the  very low product ion of 
biopharmaceuticals, Brazil is a world reference for 
the production of vaccines. The SUS makes available 
approximately 300 million vaccine doses annually, and 
96% of the components are produced nationally, mainly by 
public companies such as the Butantan Institute and Bio-
Manguinhos (http://www.brasil.gov.br/saude/2014/05/
conheca-as-vacinas-oferecidas-pelo-sus). 
Butantan Institute produces vaccines against 
diphtheria, tetanus and pertussis (DTP), adult diphtheria 
tetanus (dT), infant diphtheria tetanus (DT), recombinant 
hepatitis B, seasonal trivalent influenza and inactivated 
rabies. The institute has signed technology transfer 
agreements (TTA) with Merck Sharp and Dohme Corp 
to produce a human papillomavirus (HPV) vaccine, 
and another with GSK for the production of hepatitis A 
vaccine. In addition, projects are being developed for 
vaccines against dengue, rotavirus, and recombinant 
pertussis BCG (neonatal pertussis vaccine) (Butantan 
Institute website, Table II)
Bio-Manguinhos produces the Haemophilus 
influenza type A component, which in combination with 
the diphtheria, tetanus and pertussis components produced 
by Butantan forms the tetravalent vaccine; through the 
addition of the hepatitis B component, it also forms 
the pentavalent vaccine. This company also produces 
vaccines against yellow fever, Haemophilus influenza 
type A, meningococcal AB, 10-valent pneumococcus, 
human rotavirus, a trivalent vaccine (measles, mumps and 
rubella), and a tetravalent vaccine (chickenpox, measles, 
mumps and rubella) (Bio-Manguinhos website, Table II). 
In Brazil, vaccination is provided free of charge by 
the government, the Brazilian private vaccine market is 
therefore still in its infancy (Temporão, 2003), and the 
domination of public companies in the vaccine market 
hinders the possibility of private companies venturing 
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into vaccine production. The massive public incentives for 
vaccine production have allowed Brazil to attain a level 
of excellence in vaccine production, but innovation is 
guided by the government in this sector. Private companies 
tend to be more aligned with global innovations and can 
incorporate new technologies more rapidly than the public 
authorities. Public and private domains should therefore 
strike a balance of interests, in order to avoid hampering 
each other (Rezaie et al., 2012). Recently, following the 
increase of the number of yellow fever cases in Brazil, 
Libbs (private) and Bio-Manguinhos (public) have formed 




Biopharmaceuticals have revolutionised the treatment 
of various diseases, such as cancer, diabetes, genetic 
disorders and rheumatism. The potential represented by this 
segment of the market for the pharmaceutical industry is 
growing, but manufacturing of these substances is expensive 
and demands both skilled labour and specific plants for 
production. In Brazil, the costs of biopharmaceuticals are 
increasing, and represent the largest share of the budget of 
the SUS. Brazil is dependent on imports of these medicines. 
The government has invested in PDP via emergency 
policies. As discussed by Luchese et al. (2017), there are 
risks to the importing of outdated technology, besides the 
possibility of the transfer not being effective, resulting 
in the maintenance of imports to supply the demand. To 
change these conditions, it is necessary to strengthen the 
investment in human resources and in R&D; this will ensure 
that the Brazilian technological domain, which has been 
expanding, has the possibility to introduce technological 
improvements and to be independent in terms of the creation 
of new technologies. 
The field of traditional, chemically synthesised 
drugs has been explored for decades by scientists and the 
pharmaceutical industry. Following advances in genetic 
engineering, nanotechnology and delivery techniques, 
biopharmaceuticals now represent a new field to be 
explored; in practice, treatments with biopharmaceuticals 
have exceeded the benefits of traditional drug treatments. 
There are still many barriers to overcome, including the 
development of new biopharmaceuticals, the scaling-up of 
production and compatibility with the immune system (in 
the case of mAbs and therapeutic proteins), and these are 
big challenges. It is necessary to find a balance between 
giving people access to better treatment and generating 
profits for the pharmaceutical industry in return for the 
high amounts invested in R&D and the production of these 
biopharmaceuticals. 
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